Cannabigerol (CBG) Gummies Market Report 2026

The cannabigerol (CBG) gummies market size has grown exponentially in recent years. It will grow from $2.94 billion in 2025 to $4.28 billion in 2026 at a compound annual growth rate (CAGR) of 45.3%. The growth in the historic period can be attributed to increasing consumer interest in alternative wellness products, expansion of legal cannabinoid markets, rising awareness of minor cannabinoids, growth of edible-based cannabinoid consumption, improvements in extraction technologies.

The cannabigerol (CBG) gummies market size is expected to see exponential growth in the next few years. It will grow to $15.39 billion in 2030 at a compound annual growth rate (CAGR) of 37.8%. The growth in the forecast period can be attributed to increasing demand for targeted health solutions, expansion of regulated cannabis markets, growing focus on product transparency and labeling, rising investments in cannabinoid research, increasing adoption of gummies as preferred delivery format. Major trends in the forecast period include growing demand for functional cannabinoid edibles, rising popularity of non-psychoactive wellness products, expansion of flavor-infused cbg gummies, increasing focus on precise dosage formats, enhanced emphasis on natural ingredient sourcing.

The increased prevalence of anxiety is expected to propel the growth of the cannabigerol (CBG) gummies market going forward. Anxiety is a psychological condition characterized by persistent feelings of excessive worry, fear, and nervousness, often accompanied by physical symptoms such as restlessness, palpitations, and sweating. The rising prevalence of anxiety is driven by factors such as increasing stress levels, traumatic experiences, genetic predisposition, and environmental and lifestyle influences. Cannabigerol (CBG) gummies are increasingly used by consumers seeking anxiety relief due to CBG’s potential interaction with the endocannabinoid system, which may help regulate neurotransmitter activity and promote relaxation and emotional balance. For instance, in February 2024, according to the Australian Institute of Health and Welfare (AIHW), an Australia-based government agency, an estimated 2.26 million males (23% of the population) and 3.43 million females (34% of the population) aged 16 to 85 in Australia had experienced an anxiety disorder at some point in their lives. Therefore, the growing prevalence of anxiety is driving demand for CBG-based wellness products, supporting the growth of the CBG gummies market.

Major companies operating in the cannabigerol (CBG) gummies market are focusing on developing innovative formulations, such as gummies made with natural and plant-based ingredients, to meet rising consumer demand for clean-label, wellness-oriented cannabinoid products. Gummies with natural ingredients emphasize organic flavorings, botanical extracts, and minimal synthetic additives, appealing to health-conscious consumers seeking holistic stress and anxiety support. For example, in November 2023, Rare Cannabinoid Company, a U.S.-based health and wellness company, launched THC + CBG Relief Gummies, featuring a unique combination of Delta-9-THC, CBG, and CBD. Each green apple-flavored gummy contains 2.5 mg of Delta-9-THC, 30 mg of CBG, and 10 mg of CBD, offering a balanced formulation designed to support relaxation and physical well-being through natural cannabinoid synergy. This launch reflects the market’s shift toward multifunctional, carefully dosed cannabinoid edibles that align with wellness and mental health trends.

In October 2024, Canopy Growth Corporation, a Canada-based cannabis company, acquired Wana for an undisclosed amount. Through this acquisition, Canopy USA aims to expand its presence in the U.S. market and strengthen its hemp-derived and state-legal edibles portfolio. Wana is a U.S.-based cannabis company known for its innovative edible and ready-to-drink products, including Delta-9-THC and non-intoxicating CBD gummies. This acquisition supports Canopy Growth’s strategy to broaden its cannabinoid product offerings and capitalize on growing consumer demand for functional, wellness-focused edibles such as CBG gummies.

Major companies operating in the cannabigerol (CBG) gummies market are Demetrix Inc., Rare Cannabinoid Company, CanniLabs, Vida Optima LLC, Curaleaf Holding Inc., The Cronos Group, Charlotte's Web Holdings Inc., Hemptown USA Inc., Green Roads LLC, Lazarus Naturals Inc., Medterra CBD LLC, ENDOCA, Extract Labs, NuLeaf Naturals LLC, Isodiol International Inc., CBDistillery, Elixinol Wellness Ltd., Joy Organics, CBD American Shaman, Steves Goods, Incredibles Edibles, Sunday Scaries, CannaCare Health GmbH, FAB Nutrition LLC (FAB CBD)

North America was the largest region in the cannabigerol (CBG) gummies market in 2025. The regions covered in the cannabigerol (CBG) gummies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cannabigerol (CBG) gummies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The cannabigerol (CBG) gummies market consists of sales of pure CBG gummies, broad spectrum CBG gummies, full spectrum CBG gummies, isolate CBG gummies, and CBG-infused gummies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.